logo
I Tried the Dyson Supersonic Nural Hair Dryer and Can Never Go Back, And It's on Sale for Its Lowest Price Ever

I Tried the Dyson Supersonic Nural Hair Dryer and Can Never Go Back, And It's on Sale for Its Lowest Price Ever

CNET22-05-2025
I unwrapped the Dyson Supersonic Nural on Christmas morning and I'm not being dramatic when I say I let out a gasp. This thing had been sitting on my wishlist for months, but I never thought I'd actually own it. It felt like someone had handed me the crown jewels of hair tools. (Thanks, Mom!)
Fast-forward a few months and I can confidently say I'm obsessed with it. This isn't one of those fancy gadgets that ends up collecting dust in the back of a drawer or closet. I use it constantly, almost daily, and every time I do, I think, "Whoa, this really is that good."
The Dyson Supersonic Nural hair dryer usually isn't on sale. In fact, it's almost never on sale. But right now is the exception because for a limited time, you can find the Dyson Supersonic Nural on sale on Amazon for $399, a 20% discount from its usual $500 price tag.
For more Memorial Day deals, explore our roundup of all the live sales now, and these top Memorial Day mattress deals.
Hey, did you know? CNET Deals texts are free, easy and save you money.
How I use my super speedy Dyson hair dryer
Drying my hair used to be a whole production -- arms aching, sweating and annoyed by the end, and still somehow left with frizz and fly-aways. Now, it takes me under 10 minutes, which still kind of blows my mind. I have thick, slightly longer than shoulder-length hair that holds onto moisture like it's a job, so this is no small feat.
The Nural model has this cool feature where it senses how close it is to your scalp and adjusts the heat automatically. I didn't really get what that meant until I used it. Basically, it stops me from roasting my roots while still drying everything quickly.
The Supersonic comes with a number of attachments, including (right to left) a wide-tooth comb, a flyaway attachment, a gentle air attachment and a wave and curl diffuser.
Macy Meyer/CNET
I usually start with the smoothing nozzle when I want a sleek look, and if I'm feeling lazy or just running late, I'll just rough-dry with no attachment at all. On days when I decide to lean into my natural texture, the diffuser is a game-changer when I scrunch my hair into waves. It doesn't flatten out my curls or make them frizzy like my old dryer did.
It's also a lot quieter than I first expected and super lightweight. I've dried my whole head while half-asleep, coffee (or wine glass if it's evening time) in one hand, Dyson in the other. It really is that easy.
Why the Dyson makes a gasp-worthy gift
Honestly, this is one of those things I never would've bought for myself (hello, price tag), but now that I have it, I can't imagine going back. It's the ultimate "treat yourself" item, but in this case, someone else treated me and I'll never stop being grateful.
If you're looking for a gift that feels luxurious yet practical, this checks all the boxes. Especially now that it's on sale for Memorial Day at the lowest price ever -- seriously, now's the time.
My final thoughts
The Dyson Supersonic Nural isn't just hype; it's genuinely made my hair styling better. I don't dread drying my hair anymore. In fact, I kind of enjoy it? Which, for me, is a Christmas miracle in itself.
If you're on the fence about it or you've been eyeing it forever like I was, this Memorial Day sale might just be the nudge you need.
If you're looking for other fun gifts, here are our favorite kitchen gifts under $50. You can also read my reviews of my favorite Everything Maker, and my favorite coffee and espresso system.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Laughing Water Capital's View on Lifecore Biomedical (LFCR)
Laughing Water Capital's View on Lifecore Biomedical (LFCR)

Yahoo

time6 minutes ago

  • Yahoo

Laughing Water Capital's View on Lifecore Biomedical (LFCR)

Laughing Water Capital, an investment management company, released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the second quarter of 2025, Class A interests in Laughing Water Capital returned approximately 13.1% net of all expenses. The SP500TR and R2000 returned 10.9% and 8.5%, respectively. In addition, you can check the fund's top 5 holdings to determine its best picks for 2025. In its second quarter 2025 investor letter, Laughing Water Capital highlighted stocks such as Lifecore Biomedical, Inc. (NASDAQ:LFCR). Lifecore Biomedical, Inc. (NASDAQ:LFCR) is an integrated contract development and manufacturing organization. The one-month return of Lifecore Biomedical, Inc. (NASDAQ:LFCR) was -8.51%, and its shares gained 24.05% of their value over the last 52 weeks. On July 23, 2025, Lifecore Biomedical, Inc. (NASDAQ:LFCR) stock closed at $7.53 per share, with a market capitalization of $278.801 million. Laughing Water Capital stated the following regarding Lifecore Biomedical, Inc. (NASDAQ:LFCR) in its second quarter 2025 investor letter: "Lifecore Biomedical, Inc. (NASDAQ:LFCR) – Lifecore, our fill-finish CDMO, continues to work toward their dual goals of increasing capacity utilization and expanding margins. I continue to believe that achieving these goals is very much a 'when' rather than an 'if.' This belief was founded on global supply and demand dynamics, strengthened by the BIOSECURE Act, and reinforced by the National Security Commission delivering a report and action plan to Congress, which calls for the re-shoring of the biotech supply chain. To top it off, Trump has recently stated that pharmaceuticals manufactured abroad will be subject to 200% tariffs. Considering that building and certifying new fill-finish capacity can take 4 or 5 years, it seems that it would be much easier to partner with a company like Lifecore. A village pharmacist fulfilling a patient's medication prescription in a rural area. Lifecore Biomedical, Inc. (NASDAQ:LFCR) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 12 hedge fund portfolios held Lifecore Biomedical, Inc. (NASDAQ:LFCR) at the end of the first quarter compared to 10 in the previous quarter. In the fiscal third quarter of fiscal 2025, Lifecore Biomedical, Inc. (NASDAQ:LFCR) generated $35.2 million in revenues compared to $35.7 million for the comparable 2024 period. While we acknowledge the potential of Lifecore Biomedical, Inc. (NASDAQ:LFCR) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Lifecore Biomedical, Inc. (NASDAQ:LFCR) and shared Greenhaven Road Capital's views on the company in the company. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio

NextNav (NN) is Seeking Regulatory Play for its 5G Spectrum
NextNav (NN) is Seeking Regulatory Play for its 5G Spectrum

Yahoo

time6 minutes ago

  • Yahoo

NextNav (NN) is Seeking Regulatory Play for its 5G Spectrum

Laughing Water Capital, an investment management company, released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the second quarter of 2025, Class A interests in Laughing Water Capital returned approximately 13.1% net of all expenses. The SP500TR and R2000 returned 10.9% and 8.5%, respectively. In addition, you can check the fund's top 5 holdings to determine its best picks for 2025. In its second quarter 2025 investor letter, Laughing Water Capital highlighted stocks such as NextNav Inc. (NASDAQ:NN). NextNav Inc. (NASDAQ:NN) provides next-generation positioning, navigation, and timing (PNT) solutions. The one-month return of NextNav Inc. (NASDAQ:NN) was 2.25%, and its shares gained 88.51% of their value over the last 52 weeks. On July 23, 2025, NextNav Inc. (NASDAQ:NN) stock closed at $15.42 per share, with a market capitalization of $2.042 billion. Laughing Water Capital stated the following regarding NextNav Inc. (NASDAQ:NN) in its second quarter 2025 investor letter: "NextNav Inc. (NASDAQ:NN) – NextNav, which is our next-gen GPS and spectrum company, continues to march the ball forward in their quest to have the FCC greenlight their spectrum for 5G use. I continue to believe that the odds of NextNav succeeding are very favorable. This belief comes from the obvious, such as reading FCC filings where NextNav is specifically named, but also from more and more articles highlighting the vulnerabilities of the existing GPS system and the National Security needs of the United States. Additionally, it is hard to interpret the official FCC Twitter/X account re-tweeting articles written by NextNav's CEO as a bad sign, and perhaps most important is reading the tea leaves and digging up the scuttlebutt surrounding the various personalities involved behind the scenes. An aerial view of a bustling metropolis with internet towers in the distance. NextNav Inc. (NASDAQ:NN) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 32 hedge fund portfolios held NextNav Inc. (NASDAQ:NN) at the end of the first quarter, which was 23 in the previous quarter. NextNav Inc.'s (NASDAQ:NN) first quarter revenue increased to $1.5 million from $1 million in Q1 2024. While we acknowledge the potential of NextNav Inc. (NASDAQ:NN) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio

4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists
4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists

Yahoo

time6 minutes ago

  • Yahoo

4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists

EMERYVILLE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced podium presentations at the 43rd Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) being held in Long Beach, CA, from July 30 – August 2, 2025. ASRS 2025 Presentation Details: Title: Interim Results from the SPECTRA Phase 2a Clinical Trial Evaluating Intravitreal 4D-150 in Adults with Diabetic Macular Edema* Date/Time: Thursday, July 31, 2025 (11:35 – 11:38 a.m. PT) Presenter: David Almeida, MD, MBA, PhD, DABO, FRCSC, FASRS, Erie Retina Research, PA *Includes 52-week primary endpoint analysis and 60-week analysis (all patients have reached 60 weeks as of the data cutoff date of May 2, 2025) Title: PRISM Phase 2b Clinical Trial Evaluating Intravitreal 4D-150 in Adults with Neovascular Age-related Macular Degeneration: 52-week Results Date/Time: Friday, August 1, 2025 (11:24 – 11:27 a.m. PT) Presenter: John A. Wells, MD, FACS, Palmetto Retina Center, SC The presentations will also be available on the 4DMT website: About 4DMT 4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company's lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company's second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT. All of the Company's product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company's product candidates for the therapeutic uses for which they are being studied. Learn more at and follow us on LinkedIn. Contacts: Media: Jenn Gordondna CommunicationsMedia@ Investors: Julian PeiHead of Investor Relations and Corporate in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store